Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer

American Journal of Clinical Pathology

Volumn 119, Issue 3, 2003, Pages 381-387

  Gupta, Deepali ^a   Middleton, Lavinia P ^b   Whitaker, Marion J ^c   Abrams, Jacki ^a,c  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

Breast cancer; Chromogenic in situ hybridization; CISH; FISH; Fluorescence in situ hybridization; HER 2 neu

Indexed keywords

CHROMOGENIC SUBSTRATE; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ACCURACY; ARTICLE; BREAST CARCINOMA; CANCER INFILTRATION; CELL STRUCTURE; CHEMICAL LABELING; CHROMOGENIC IN SITU HYBRIDIZATION; CHROMOSOME 17; CHROMOSOME ABERRATION; CLINICAL ARTICLE; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENE PROBE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MICROSCOPY; ONCOGENE NEU; POLYSOMY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SIGNAL DETECTION; TECHNIQUE; TISSUE SECTION; BREAST TUMOR; CELL NUCLEUS; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; GENETICS; METABOLISM; PAGET NIPPLE DISEASE; PATHOLOGY; PROTO ONCOGENE; REPRODUCIBILITY; VALIDATION STUDY;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL NUCLEUS; GENES, ERBB-2; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS;

EID: 0037362714     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/P40P2EAD42PUKDMG     Document Type: Article

References (22)

1. Sahin AA. Biologic and clinical significance of HER-2/neu (c-erbB-2) in breast cancer. Adv Anat Pathol. 2000;7:158-166.
2. Baselga J. Herceptin alone or in combination with chemotherapy in the treatment of HER-2-positve metastatic breast cancer: pivotal trials. Oncology. 2001;61(suppl 2):14-21.
3. Hynes NE. Amplification and overexpression of the erbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy. Semin Cancer Biol. 1993;4:19-26.
4. Cell Markers and Cytogenetics Committees College of American Pathologists. Clinical laboratory assays for HER-2/neu amplification and overexpression: quality assurance, standardization, and proficiency testing. Arch Pathol Lab Med. 2002;126:803-808.
5. Hanna W. Testing for HER-2 status. Oncology. 2001;61(suppl 2):22-30.
6. Press MF, Hung G, Godolphin W, et al. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res. 1994;54:2771-2777.
7. Jacobs TW, Gown AM, Yaziji H, et al. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol. 1999;17:1983-1987.
8. Penault-Llorca F, Adelaide J, Houvenaeghel G, et al. Optimization of immunohistochemical detection of erbB-2 in human breast cancer: impact of fixation. J Pathol. 1994;173:65-75.
9. Farabegoli F, Ceccarelli C, Santini D, et al. c-erbB-2 overexpression in amplified and non-amplified breast carcinoma samples. Int J Cancer. 1999;84:273-277.
10. Kay EW, Walsh CJ, Cassidy M, et al. c-erbB-2 immunostaining: problems with interpretation. J Clin Pathol. 1994;47:816-822.
11. Vang R, Cooley LD, Harrison WR, et al. Immunohistochemical determination of HER-2/neu expression in invasive breast carcinoma. Am J Clin Pathol. 2000;113:669-674.
12. Pauletti G, Godolphin W, Press M, et al. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. 1996;13:63-72.
13. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer, I: the value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403-410.
14. Tanner M, Gancberg D, Di Leo A, et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol. 2000;157:1467-1472.
15. Hopman AH, Ramaekers FC, Raap AK, et al. In situ hybridization as a tool to study numerical chromosome aberrations in solid bladder tumors. Histochemistry. 1988;89:307-316.
16. Kumamoto H, Sasano H, Taniguchi T, et al. Chromogenic in situ hybridization analysis of HER-2/neu status in breast carcinoma: application in screening of patients for trastuzumab (Herceptin) therapy. Pathol Int. 2001;51:579-584.
17. Zhao J, Wu R, Au A, et al. Determination of HER-2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma. Mod Pathol. 2002;15:657-665.
18. Dandachi N, Dietze O, Hauser-Kronberger C. Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma. Lab Invest. 2002;82:1007-1014.
19. Tubbs R, Skacel M, Pettay J, et al. Interobserver interpretative reproducibility of GOLDFISH, a first generation gold-facilitated autometallographic bright field in situ hybridization assay for HER-2/neu amplification in invasive mammary carcinoma. Am J Surg Pathol. 2002;26:908-913.
20. Tubbs R, Pettay J, Skacel M, et al. Gold -facilitated in situ hybridization: a bright-field autometallographic alternative to fluorescence in situ hybridization for detection of HER-2/neu gene amplification. Am J Pathol. 2002;160:1589-1595.
21. Bose S, Mohammed M, Shintaku P, et al. Her-2/neu gene amplification in low to moderately expressing breast cancers: possible role of chromosome 17/HER-2/neu polysomy. Breast J. 2001;7:337-344.
22. Hoff EF, Tubbs RR, Myles JL, et al. HER-2/neu amplification in breast cancer: stratification by tumor type and grade. Am J Clin Pathol. 2002;117:916-921.